louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04192526: Serum Cholinesterase Level in Aluminum Phosphide Poisoning, the Possible Proposing Role of Atropin & Pralidoxime
Official title: Assessment of Serum Cholinesrtrase Level in Aluminum Phosphide Poisoning Cases, the Possible Proposing Role of Atropine and Pralidoxime in Saving the Cases: Clinical and
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Toxicity;Chemical
Keywords: serum cholinestrase, atropin, aluminum phosphide
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-12-10
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cases of aluminum phosphide poisoning attending Assiut University Hospitals

Brief summary: Metal phosphides are widely used as a rodenticide and insecticide and poisoning with these substances has a very high mortality. The aim of this study was to evaluate the butyrylcholinesterase (BuCh) level in poisoning with metal phosphides.

Detailed description: Today, the use of pesticides in the world is considered as a recognized health It is estimated that around 30% of global suicides are due to pesticide self-poisoning . Metal phosphides pesticides are highly toxic, low cost, and are easily accessible as rodenticide agents and used for self-poisoning . aluminum phosphide (ALP) are among the most important metal phosphides. Poisoning with these agents is frequently seen in India, Srilanka and Iran. In a recent study, the incidence of fatal aluminum phosphide poisoning cases referred for phosphine analysis was 5.22 and 37.02 per million of population of Tehran, Iran in 2006 and 2013, respectively (9).The mechanism of toxicity is not clearly defined. ALP toxicity is related to the production of phosphine gas. Phosphine inhibits cytochrome c oxidase and causes mitochondrial destruction and inhibits oxidative respiration which leads to anaerobic metabolism, severe metabolic acidosis, multi-organ dysfunction and death. Phosphine can lead to severe cardiac suppression and cardiogenic shock. One of the proposed mechanisms of toxicity is the reduction of the true cholinesterase and serum cholinesterase (butyrylcholinesterase) enzyme, but usually do not show obvious clinical manifestations .

Eligibility criteria: Inclusion Criteria: cases of aluminum phosphide poisoning -

Exclusion Criteria: concomitant ingestion

-

Primary outcomes:
measure: persistent cholineastrase inhibition is one of the pathological pathway of the ALP poisoning
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: AssiutU
Study officials:
affiliation: AssiutU, faculty of medicine
name: Doaa Abd el rahman
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05019326: Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19
Official title: A Two-stage Adaptive Randomized Controlled Trial of Andrographis Paniculata Extract, Boesenbergia Rotunda Extract, and Standard Treatment in Asymptomatic COVID-19 Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Covid19
Keywords: Treatment
Andrographis
Boesenbergia
Covid19
Lead sponsor: Mahidol University
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Thailand
First posted: 2021-08-24
Enrollment: 3060
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the effect of Andrographis Extract, Boesenbergia Extract compared to standard treatment in asymptomatic COVID patients.


Eligibility criteria: Inclusion Criteria:

1. Age 18- 60 years old
2. Have been diagnosed as new COVID-19 case by RT-PCR since disease onset to admission less than 7 days
3. Have asymptomatic infection assessed by the World Health Organization (WHO) disease category
4. Do not have any of following disease or conditions

   1. Body weight \> 90 kg or BMI \> 30 kg/m2
   2. Hypertension that needs antihypertensive medication
   3. Diabetes
   4. Cardiovascular diseases including congenital heart disease
   5. Cerebrovascular diseases
   6. Chronic kidney and chronic liver diseases
   7. COPD or chronic lung diseases
   8. Lymphocyte \<1,000 cells/mm3
   9. Late-stage cancer
   10. Auto-immune disease (e.g., SLE, Rheumatoid arthritis, multiple sclerosis, etc.) or currently on immunosuppressive drug
   11. Coagulation disorders or platelet disorders and are being treated with anticoagulants such as warfarin, clopidogrel
   12. Pregnancy
5. Willing to participate with the study and sign inform consents.

(Withdrawal criteria)

1. Patients withdraw from the study
2. Have severe adverse effect that may relate to Andographolide or Boesenbergia

Primary outcomes:
measure: Require hospitalization in the hospital
timeFrame: 28 days
Secondary outcomes:
measure: Individual status from WHO clinical progression scale (0-10)
timeFrame: 28 days
measure: Pneumonia
timeFrame: 28 days
measure: Quality of life by EQ5D-5L
timeFrame: 28 days
measure: Side effect of medication
timeFrame: 28 days
Other outcomes:
Locations:
city: Ratchathewi
country: Thailand
facility: Faculty of Medicine Ramathibodi Hospital
state: Bangkok
Study officials:
References:
Clinical trial NCT02615626: Visfatin Levels Before and After Periodontal Treatment
Official title: Gingival Crevicular Fluid and Serum Levels of Visfatin in Periodontal Diseases Before and After Non-surgical Periodontal Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontal Diseases
Keywords: Visfatin
GCF
serum
Non-surgical Periodontal Treatment.
Lead sponsor: Bulent Ecevit University
Sponsor class: OTHER
First posted: 2015-11-26
Enrollment: 45
Sex: ALL
Minimum age (years): 25
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Total of 45 patients

Brief summary: The purpose of this study was to evaluate visfatin levels in different stages of periodontal diseases and health, moreover the effect of non-surgical periodontal therapy on visfatin levels in Gingival Crevicular Fluid (GCF) and Serum.

Detailed description: Total of 45 patients were divided into three groups based on their clinical and radiographical examination. Group 1 chronic periodontitis (n: 15), group 2 plaque induced gingivitis (n: 15) and group 3 Periodontal health (n: 15). GCF and serum samples were collected before treatment and 1, 3, 6 months after treatment and were assayed using enzyme linked immunosorbent assay kit.

Eligibility criteria: Group 1 Inclusion Criteria:

* GI\>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically.
* Systematically healthy patients

Group 2 Inclusion Criteria:

* No alveolar bone and attachment loss
* Inflammation signs such as redness, edema and increased BOP levels,
* GI≥2, PPD≤3mm, CAL≤3mm.
* Systematically healthy patients

Group 3 Inclusion Criteria:

* No bone and attachment loss,
* GI=0, PPD≤3mm, CAL≤3mm
* Systematically healthy patients

Exclusion Criteria for all groups:

* Aggressive Periodontitis,
* Oral pathologies,
* Patients with any other systemic diseases,
* Pregnant women and those in the lactation period,
* Patients with smoking habit and taking medication
* Patients received periodontal therapy in last 6 months

Primary outcomes:
measure: Visfatin levels: Change after periodontal treatment both in serum and GCF
timeFrame: baseline, 1, 3 and 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: BULENT ECEVIT UNIVERSITY FACULTY OF DENTISTRY DEPARTMENT OF PERIODONTOLOGY
name: ÇİĞDEM COŞKUN TÜRER, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02533726: Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers
Official title: Randomized Control Trial Evaluating Optimal Patient Turning Procedures for Reducing Hospital Acquired Pressure Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pressure Ulcer
Keywords: Bed Sores
Bedsores
Decubitus Ulcer
Pressure Sore
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: Leaf Healthcare, Inc.
First posted: 2015-08-27
Enrollment: 1312
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to test whether optimal patient turning, strictly every 2 hours with at least 15 minutes of tissue decompression, reduces the occurrence of hospital acquired pressure ulcers.

Detailed description: This single site, open label, two arm randomized control trial aims to evaluate whether optimal patient turning, strictly every 2 hours with at least 15 minutes of tissue decompression, reduces the occurrence of hospital acquired pressure ulcers. Optimal turning procedures will be obtained with the use of a patient monitoring system (Leaf Healthcare, Inc.) and compared to standard preventative care practices.

Sensors were placed on all participants as they were admitted to ICU. A nurse's user dashboard was turned on for participants in the Optimal Turning Group, but was not turned on for participants in the Standard Care group.

Eligibility criteria: Inclusion Criteria:

* Adults (\>18 years of age)
* Admission to Intensive Care Unit

Exclusion Criteria:

* Children (\<18 years of age)
* Adhesive allergy
* Physical limitation for sensor application

Primary outcomes:
measure: Count of Participants With Pressure Ulcer According to the National Pressure Ulcer Advisory Panel (NPUAP) Criteria for Pressure Ulcers
timeFrame: Duration of ICU admission (average 1 week)
Secondary outcomes:
measure: Compliance With Patient Turning Procedures
timeFrame: Duration of ICU admission (average 1 week)
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Health Care
state: California
Study officials:
affiliation: Stanford Health Care
name: David Pickham, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pickham D, Ballew B, Ebong K, Shinn J, Lough ME, Mayer B. Evaluating optimal patient-turning procedures for reducing hospital-acquired pressure ulcers (LS-HAPU): study protocol for a randomized controlled trial. Trials. 2016 Apr 6;17:190. doi: 10.1186/s13063-016-1313-5.
Clinical trial NCT01275326: Indoor Air Quality and Infectious Aerosols in Health Care Facilities
Official title: Indoor Air Quality and Infectious Aerosols in Health Care Facilities
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Indoor Air Quality
Infectious Aerosols
Keywords: Indoor Air Quality
Infectious Aerosols
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
First posted: 2011-01-12
Enrollment: 120
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Sampling method: PROBABILITY_SAMPLE
Study population: people who work in Health Care Facilities

Brief summary: Outbreaks of emerging and re-remerging infectious diseases are frequently reported internationally in recent years, mainly due to global climate change, close human-livestock contact in developing countries, and globalization. Thus prevention, monitoring and control of infectious diseases are in urgent need to protect public health. High exposure risk to various infectious agents in health care facilities is of special concern, especially to airborne and droplet-borne respiratory diseases. To protect the health of public and health care workers the investigators will conduct a study to monitor indoor air quality and essential infectious aerosols in hospital(s).

A questionnaire survey will be used to evaluate the relationships between employees' health and measured indoor environmental factors. The investigators will also examine whether the current indoor air quality recommendation of their country can reasonably reduce the risk of hospital infection. In addition, simple infectious aerosol indices will be established for future environmental management and monitoring in health care facilities.


Eligibility criteria: Inclusion Criteria:

* people who work in Health Care Facilities

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University
Study officials:
affiliation: Taipei Medical University
name: Hsing Chao
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02453126: Fibrostenotic Eosinophilic Esophagitis: Assessment Tools
Official title: Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Eosinophilic Esophagitis
Keywords: Eosinophilic Esophagitis
Esophageal Stricture
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2015-05-25
Enrollment: 250
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children, ages 5 to 18 years, scheduled to undergo a clinical upper endoscopy with biopsy for suspected or confirmed Eosinophilic Esophagitis.

Brief summary: This protocol addresses a central hypothesis that fibrostenotic Eosinophilic Esophagitis (EoE) is characterized by abnormal esophageal structure and compliance compared to non fibrostenotic EoE and that distinctive cellular and molecular profiles predict the fibrostenotic phenotype. This study aims to define and assess the changes that occur in the structure and dynamics of the esophageal wall in pediatric Eosinophilic Esophagitis along with characterizing the histologic and molecular patterns in fibrostenotic EoE.


Eligibility criteria: Inclusion Criteria:

* Scheduled to undergo a clinical upper endoscopy with biopsy

Exclusion Criteria:

* Known connective tissue disorder
* Increased risk of bleeding
* Inflammatory bowel disease, celiac disease, eosinophilic gastroenteritis, or any autoimmune disease
* Other esophageal disease including known achalasia; history of caustic ingestion, esophageal surgery esophageal stricture for other known reason or other esophageal injury.
* Use of oral or intravenous steroids in the preceding 60 days. (Swallowed topical fluticasone, budesonide, etc not included as exclusion criteria.)

Primary outcomes:
measure: Stricture, as measured by endoscopic assessment
timeFrame: Day 1
Secondary outcomes:
measure: Decreased esophageal distensibility, as determined by EndoFlip
timeFrame: Day 1
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado
state: Colorado
Study officials:
affiliation: University of Colorado/Childrens Hospital Colorado
name: Calies Menard-Katcher, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02106026: Nursing Education Intervention for Maternal Breastfeeding
Official title: Effectiveness of a Nursing Education Intervention on Duration of Breastfeeding and on Post-natal Breast Complications in Primiparous Women: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Feeding
Postpartum Breast Disorders
Keywords: Breastfeeding
Nursing
Patient Education as Topic
Health Knowledge, Attitudes, Practice
Hispanic Americans.
Lead sponsor: Universidad Miguel Hernandez de Elche
Sponsor class: OTHER
First posted: 2014-04-07
Enrollment: 314
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: An antenatal education intervention in primiparous women improves breastfeeding duration and reduces post-natal complications.

Detailed description: A randomized controlled clinical trial of an educational intervention was undertaken at a public hospital. the investigators compared a health education based on techniques to prevent complications and increase information about the benefits of breastfeeding with the usual practice. A group of nurses delivered the educational intervention. The trial involved randomization of 314 primiparous women. The analysis was by 'intention-to-treat'.

Eligibility criteria: Inclusion Criteria:

* primiparous women,
* no contraindications to breastfeeding,
* no skin disorders,
* no breast surgery,
* voluntary provision of data to enable their later localization.

Exclusion Criteria:

* women who planned to deliver their babies in other hospitals,
* twin pregnancy

Primary outcomes:
measure: Breastfeeding duration
timeFrame: At 6 months postpartum
measure: Breastfeeding duration
timeFrame: At 1 month postpartum
Secondary outcomes:
measure: Knowledge about breastfeeding and care of the breasts,
timeFrame: Inmediate postpartum period.
measure: Incidence of mothers with post-natal breast complications, such as cracks, breast lesions or mastitis
timeFrame: At 1 month postpartum
Other outcomes:
Locations:
Study officials:
affiliation: Universidad Miguel Hernandez de Elche
name: Concepcion Carratala-Munuera, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04858126: Accuracy of ECOM Plus Versus Pulmonary Artery Catheter
Official title: Accuracy of the ECOM Plus Hemodynamic Monitor Versus Pulmonary Artery Catheter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodynamic Monitoring
Lead sponsor: ECOM Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2021-04-26
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This Study will compare the accuracy of the ECOM Plus Endotracheal Cardiac Output Monitor (ECOM) without the use of the arterial pressure waveform from the arterial line to 1) the current clinical standard of cardiac output measured by intermittent room temperature bolus thermodilution using a PAC, 2) the current ECOM System with the use of the arterial blood pressure waveform from a radial arterial line and 3) the Flo-Trac® System.

Detailed description: This Study will compare the accuracy of the ECOM Plus Endotracheal Cardiac Output Monitor (ECOM) without the use of the arterial pressure waveform from the arterial line to 1) the current clinical standard of cardiac output measured by intermittent room temperature bolus thermodilution using a PAC, 2) the current ECOM System with the use of the arterial blood pressure waveform from a radial arterial line and 3) the Flo-Trac® System (Edwards LifeSciences).

Eligibility criteria: Inclusion Criteria:

* Patients able to give informed consent.
* Patients undergoing surgery that would routinely require use of an endotracheal, pulmonary artery catheter and arterial catheter.

Exclusion Criteria:

* Patients who do not speak English.
* Patients not competent to give informed consent.

Primary outcomes:
measure: Comparison of ECOM Plus impedance and thermal dilution cardiac output measurements
timeFrame: 6 months.
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: VA San Francisco
state: California
Study officials:
affiliation: VA San Francisco
name: Arthur Wallace, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wallace AW, Salahieh A, Lawrence A, Spector K, Owens C, Alonso D. Endotracheal cardiac output monitor. Anesthesiology. 2000 Jan;92(1):178-89. doi: 10.1097/00000542-200001000-00030.
Clinical trial NCT00880126: Community Development Teams to Scale-Up Multidimensional Treatment Foster Care (MTFC) in California
Official title: Community Development Teams to Scale-Up MTFC in California
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Behavior Problems
Keywords: Individualized Implementation
Community Development Teams
Lead sponsor: Center for Research to Practice
Sponsor class: OTHER
First posted: 2009-04-13
Enrollment: 350
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effects of using Community Development Teams to increase the number of counties that successfully implement and sustain Multidimensional Treatment Foster Care programs is studied in a randomized trial in 40 California counties. MTFC is an alternative to group or residential placement for youth with severe conduct and emotional problems referred from the juvenile justice and child welfare systems.


Eligibility criteria: Inclusion Criteria:

* Non-early adopters of evidence-based practice (MTFC)

Exclusion Criteria:

* Placed fewer than 6 youth per year in group care

Primary outcomes:
measure: Implementation of an evidence-based practice in counties
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Brown CH, Chamberlain P, Saldana L, Padgett C, Wang W, Cruden G. Evaluation of two implementation strategies in 51 child county public service systems in two states: results of a cluster randomized head-to-head implementation trial. Implement Sci. 2014 Oct 14;9:134. doi: 10.1186/s13012-014-0134-8.
citation: Palinkas LA, Holloway IW, Rice E, Brown CH, Valente TW, Chamberlain P. Influence network linkages across implementation strategy conditions in a randomized controlled trial of two strategies for scaling up evidence-based practices in public youth-serving systems. Implement Sci. 2013 Nov 14;8:133. doi: 10.1186/1748-5908-8-133.
citation: Palinkas LA, Holloway IW, Rice E, Fuentes D, Wu Q, Chamberlain P. Social networks and implementation of evidence-based practices in public youth-serving systems: a mixed-methods study. Implement Sci. 2011 Sep 29;6:113. doi: 10.1186/1748-5908-6-113.